Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Venetoclax With HMAs Shows Promise in AML for Patients Ineligible for High-Dose Chemo
More than 70% of older patients ineligible for intensive chemotherapy for acute myeloid leukemia had complete responses to venetoclax combined with hypomethylating agents, preliminary results from clinical trials have shown.
Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma
The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.
Dr. Leonard on AUGMENT Trial Results in Non-Hodgkin Lymphoma
December 3rd 2018John P. Leonard, MD, associate dean for clinical research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, discusses the key takeaway from the phase III AUGMENT trial, a randomized study of lenalidomide (Revlimid) plus rituximab (Rituxan) (R2) versus rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma, during the 2018 ASH Annual Meeting.
Dr. Gauthier on Findings for CD19-Targeted CAR T Cells Plus Ibrutinib in CLL
December 3rd 2018Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses a study comparing efficacy and toxicity of CD19-specific chimeric antigen receptor (CAR) T cells alone or in combination with ibrutinib in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) during the 2018 ASH Annual Meeting.
Beat AML Trial Proves Feasibility of Rapid Treatment Assignment Following Diagnosis
December 3rd 2018Initial findings from the Beat AML study showed that rapid genetic testing in patients with AML was feasible and helpful, and that a precision medicine approach is possible for these patients, who must be treated urgently given the disease’s rapid progression.
Liso-Cel Demonstrates Durable Responses in Heavily Pretreated, High-Risk CLL
December 3rd 2018Lisocabtagene maraleucel appeared tolerable and induced an 81.3% best overall response rate and 43.8% complete response rate in heavily pretreated, high-risk patients with chronic lymphocytic leukemia who previously received ibrutinib.
Maintenance Ixazomib Extends PFS in Newly Diagnosed Multiple Myeloma
December 3rd 2018Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.
Ibrutinib/Venetoclax Combination Achieves High Rate of MRD Negativity in Relapsed/Refractory CLL
The combination of ibrutinib and venetoclax is well tolerated and eradicates minimal residual disease in the marrow after 12 months in 39% of patients with relapsed/refractory chronic lymphocytic leukemia.
Daratumumab Safe and Effective When Added to VRd in Newly Diagnosed MM
Daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients and a stringent complete response or CR in 63% of patients at the end of consolidation therapy in the run-in phase of an open-label study of transplant-eligible patients with newly diagnosed multiple myeloma.
First HCT Following CAR T-Cell Therapy Reduces Risk for ALL Relapse
December 2nd 2018Receiving a stem cell transplant for the first time following CD19 CAR T-cell therapy induced a reduction in the risk for acute lymphoblastic leukemia (ALL) recurrence, according to a retrospective analysis of the phase I/II PLAT-02 study.
Dr. Ravandi on BiTE Antibody AMG 330 Data in Relapsed/Refractory AML
December 2nd 2018Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase I first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE) antibody construct, in patients with relapsed/refractory acute myeloid leukemia (AML) during the 2018 ASH Annual Meeting.
Dr. Phillips on Activity With Acalabrutinib Plus Bendamustine/Rituximab in MCL
December 2nd 2018Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.
Tisagenlecleucel Benefit Sustained in DLBCL Follow-Up
Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.
Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL
Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.
Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC Options
November 13th 2018In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.
